Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Literature DB >> 23803901

Immunogenicity analysis of Staphylococcus aureus clumping factor A genetic variants.

Rebecca A Brady¹, Christopher P Mocca, Drusilla L Burns.

Abstract

The staphylococcal adhesin clumping factor A (ClfA) has a variant amino acid sequence, generating the potential for alterations in epitope structure and immunogenicity of this vaccine candidate. We demonstrated for two recombinant ClfA(40-531) (a slightly truncated version of the fibrinogen-binding domain of ClfA containing amino acids 40 to 531) genetic variants that strain-specific epitopes are immunodominant. This work indicates that immune responses elicited by ClfA may, at least in part, be dependent on the strain of origin of the ClfA.

Entities: Chemical Species

Mesh：

Substances：

Year: 2013 PMID： 23803901 PMCID： PMC3754511 DOI： 10.1128/CVI.00275-13

Source DB: PubMed Journal: Clin Vaccine Immunol ISSN： 1556-679X

18 in total

1. Antibodies to capsular polysaccharide and clumping factor A prevent mastitis and the emergence of unencapsulated and small-colony variants of Staphylococcus aureus in mice.

Authors: Lorena P N Tuchscherr; Fernanda R Buzzola; Lucía P Alvarez; Jean C Lee; Daniel O Sordelli
Journal: Infect Immun Date: 2008-09-22 Impact factor: 3.441

2. Protection against experimental Staphylococcus aureus arthritis by vaccination with clumping factor A, a novel virulence determinant.

Authors: E Josefsson; O Hartford; L O'Brien; J M Patti; T Foster
Journal: J Infect Dis Date: 2001-12-03 Impact factor: 5.226

3. A recombinant clumping factor A-containing vaccine induces functional antibodies to Staphylococcus aureus that are not observed after natural exposure.

Authors: Julio Hawkins; Srinivas Kodali; Yury V Matsuka; Lisa K McNeil; Terri Mininni; Ingrid L Scully; John H Vernachio; Elena Severina; Douglas Girgenti; Kathrin U Jansen; Annaliesa S Anderson; Robert G K Donald
Journal: Clin Vaccine Immunol Date: 2012-08-15

4. Identification of the ligand-binding domain of the surface-located fibrinogen receptor (clumping factor) of Staphylococcus aureus.

Authors: D McDevitt; P Francois; P Vaudaux; T J Foster
Journal: Mol Microbiol Date: 1995-06 Impact factor: 3.501

5. Vaccine assembly from surface proteins of Staphylococcus aureus.

Authors: Yukiko K Stranger-Jones; Taeok Bae; Olaf Schneewind
Journal: Proc Natl Acad Sci U S A Date: 2006-10-30 Impact factor: 11.205

6. c-di-GMP as a vaccine adjuvant enhances protection against systemic methicillin-resistant Staphylococcus aureus (MRSA) infection.

Authors: Dong-Liang Hu; Kouji Narita; Mamoru Hyodo; Yoshihiro Hayakawa; Akio Nakane; David K R Karaolis
Journal: Vaccine Date: 2009-05-09 Impact factor: 3.641

7. Characterization of a protective monoclonal antibody recognizing Staphylococcus aureus MSCRAMM protein clumping factor A.

Authors: Andrea E Hall; Paul J Domanski; Pratiksha R Patel; John H Vernachio; Peter J Syribeys; Elena L Gorovits; Michael A Johnson; Julia M Ross; Jeff T Hutchins; Joseph M Patti
Journal: Infect Immun Date: 2003-12 Impact factor: 3.441

8. Vaccination with clumping factor A and fibronectin binding protein A to prevent Staphylococcus aureus infection of an aortic patch in mice.

Authors: Carlos Arrecubieta; Iwao Matsunaga; Tomohiro Asai; Yoshifumi Naka; Mario C Deng; Franklin D Lowy
Journal: J Infect Dis Date: 2008-08-15 Impact factor: 5.226

9. Fibrinogen binding sites P336 and Y338 of clumping factor A are crucial for Staphylococcus aureus virulence.

Authors: Elisabet Josefsson; Judy Higgins; Timothy J Foster; Andrej Tarkowski
Journal: PLoS One Date: 2008-05-21 Impact factor: 3.240

10. A structural model of the Staphylococcus aureus ClfA-fibrinogen interaction opens new avenues for the design of anti-staphylococcal therapeutics.

Authors: Vannakambadi K Ganesh; Jose J Rivera; Emanuel Smeds; Ya-Ping Ko; M Gabriela Bowden; Elisabeth R Wann; Shivasankarappa Gurusiddappa; J Ross Fitzgerald; Magnus Höök
Journal: PLoS Pathog Date: 2008-11-28 Impact factor: 6.823

5 in total

1. Safety and immunogenicity of an investigational 4-component Staphylococcus aureus vaccine with or without AS03B adjuvant: Results of a randomized phase I trial.

Authors: Jack Levy; Laurent Licini; Edwige Haelterman; Philippe Moris; Pascal Lestrate; Silvia Damaso; Pascale Van Belle; Dominique Boutriau
Journal: Hum Vaccin Immunother Date: 2015 Impact factor: 3.452

2. Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.

Authors: C Tkaczyk; S Kasturirangan; A Minola; O Jones-Nelson; V Gunter; Y Y Shi; K Rosenthal; V Aleti; E Semenova; P Warrener; D Tabor; C K Stover; D Corti; G Rainey; B R Sellman
Journal: Antimicrob Agents Chemother Date: 2017-07-25 Impact factor: 5.191